Community-acquired Bacterial Pneumonia Clinical Trial
— publicOfficial title:
A Phase 3b Randomized, Double-blind, Multi-center Study to Compare the Safety and Efficacy of Omadacycline IV/PO to Moxifloxacin IV/PO for Treating Adult Subjects With Community-acquired Bacterial Pneumonia (CABP)
The primary objective of the study is to show that in Chinese adults with CABP, a course of IV/PO treatment with omadacycline has similar clinical efficacy as the with the comparator antibiotic, IV/PO moxifloxacin. The study is designed as a bridging study, to confirm the results of the pivotal global CABP trial in an ethnically different population of Chinese.
Status | Recruiting |
Enrollment | 100 |
Est. completion date | November 30, 2025 |
Est. primary completion date | January 1, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Written and signed informed consent obtained before any protocol specific assessment is performed. 2. Male or female, ages 18 years or older. 3. Has at least 3 of the following symptoms: - Cough - Production of purulent sputum - Dyspnea (shortness of breath) - Chest pain 4. Has at least 2 of the following abnormal vital signs: - Fever or hypothermia documented by the investigator (temperature > 38.0°C or < 36.0°C) - Hypotension with systolic blood pressure (SBP) < 90 mmHg - Heart rate (HR) > 90 beats per minute (bpm) - Respiratory rate (RR) > 20 breaths/minute Exclusion Criteria: 1. Has received antibacterial treatment >24hr within the 72hr window prior to randomization. Subjects may be eligible despite prior antibacterial therapy if they had been treated with short action time antimicrobial for =24h, or if they have received > 48 hours of prior systemic antibacterial therapy for the current episode of CABP with unequivocal clinical evidence of treatment failure. 2. Is known or suspected to have CABP caused by a pathogen that may be resistant to either test article (eg, Klebsiella pneumoniae, Pseudomonas aeruginosa, Pneumocystis jiroveci, obligate anaerobes, mycobacteria, fungal pathogens). 3. Suspected or confirmed empyema (a parapneumonic pleural effusion is not an exclusion criteria) or lung abscess. - |
Country | Name | City | State |
---|---|---|---|
United States | Zai Lab Site 2023 | Fairfax | Virginia |
United States | Zai Lab Site 2016 | Lynwood | California |
United States | Zai Lab Site 2025 | New York | New York |
United States | Zai Lab Site 2022 | Tacoma | Washington |
Lead Sponsor | Collaborator |
---|---|
Zai Lab (Hong Kong), Ltd. |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Overall assessment of clinical response rate at post therapy evaluation (PTE) timepoint in the mITT population. | 18 months | ||
Secondary | Clinical response rate at the Early Clinical Response (ECR) assessment (72 to 120 hours after administration of the first dose of test article) in the mITT population. | 72 to 120 hours | ||
Secondary | Clinical response rate at the End of Treatment (EOT) assessment in the mITT and CE population. | 18 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01968733 -
Efficacy and Safety Study of Intravenous to Oral Solithromycin (CEM-101) Compared to Intravenous to Oral Moxifloxacin in Treatment of Patients With Community-Acquired Bacterial Pneumonia
|
Phase 3 | |
Completed |
NCT01072539 -
Study Evaluating The Safety And Effectiveness In Subjects With Tigecycline Treatment
|
||
Completed |
NCT01756339 -
Efficacy and Safety Study of Oral Solithromycin (CEM-101) Compared to Oral Moxifloxacin in Treatment of Patients With Community-Acquired Bacterial Pneumonia
|
Phase 3 | |
Completed |
NCT01371838 -
A Study to Evaluate the Efficacy and Safety of Intravenous Ceftaroline Versus Intravenous Ceftriaxone in the Treatment of Adult Hospitalised Patients With Community-Acquired Bacterial Pneumonia in Asia
|
Phase 3 | |
Completed |
NCT01168713 -
Efficacy and Safety Study of Oral CEM-101 Compared to Oral Levofloxacin in Treatment of Patients With Community-Acquired Bacterial Pneumonia
|
Phase 2 | |
Terminated |
NCT02605122 -
Safety and Efficacy of Solithromycin in Adolescents and Children With Community-Acquired Bacterial Pneumonia
|
Phase 2/Phase 3 |